Ironwood Pharmaceuticals Stock News

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) COO Jason Rickard sold 17,193 shares of the firm’s stock in a transaction that occurred on Tuesday, November 23rd. The stock was sold at an average price of $11.58, for a total transaction of $199,094.94. The sale was disclosed in a document filed with the SEC, which can be accessed through […]

Price T Rowe Associates Inc. MD decreased its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 12.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 132,845 shares of the biotechnology companys stock after selling 18,069 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in Ironwood Pharmaceuticals were worth $1,710,000 as []

Wall Street brokerages expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report sales of $109.58 million for the current quarter, according to Zacks. Two analysts have provided estimates for Ironwood Pharmaceuticals earnings, with the highest sales estimate coming in at $110.16 million and the lowest estimate coming in at $109.00 million. Ironwood Pharmaceuticals reported sales of $116.68 []

Marshall Wace LLP grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 3,037.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 418,870 shares of the biotechnology companys stock after acquiring an additional 405,520 shares during the quarter. Marshall Wace LLPs holdings in Ironwood []

LPL Financial LLC raised its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 139.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,965 shares of the biotechnology companys stock after purchasing an additional 13,965 shares during the period. LPL Financial LLCs []

Analysts predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will post earnings per share of $0.31 for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Ironwood Pharmaceuticals earnings, with the highest EPS estimate coming in at $0.36 and the lowest estimate coming in at $0.28. Ironwood Pharmaceuticals reported earnings of $0.36 per []

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q3 2021 Results - Earnings Call Transcript

Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance.

Ironwood (IRWD) delivered earnings and revenue surprises of 6.45% and -1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.

P/E (5.61), EV/EBITDA (9.28), and Price/Sales (5.37) are 30-80% lower than the sector medians.

The Baby Boomers are getting older, which means investors should consider adding undervalued healthcare stocks to their portfolio. The post 3 Cheap Healthcare Stocks to Buy Right Now appeared first on

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September: 2021 Wells Fargo Healthcare Confere

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q2 2021 Results - Earnings Call Transcript

Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.